What's Happening?
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial for modzatinib (ATI-2138). This trial will evaluate the efficacy, safety, and tolerability
of modzatinib in patients suffering from moderate-to-severe lichen planus (LP). The initial cohort will focus on patients with oral erosive lichen planus (OLP). The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to modzatinib for moderate-to-severe LP. Modzatinib is an investigational pharmacologic agent designed as a dual inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), targeting key pathways involved in LP pathology. Lichen planus is a chronic, immune-mediated inflammatory disease affecting approximately 0.1% to 2% of the global population, with no FDA-approved targeted therapeutic options currently available.
Why It's Important?
The initiation of this Phase 2b trial and the FDA's Fast Track Designation for modzatinib are significant developments for patients with lichen planus, a debilitating disease with substantial unmet medical needs. The absence of FDA-approved therapies means current management relies on immunosuppression and topical symptom control, which often fall short for moderate-to-severe cases. Modzatinib's unique dual inhibition mechanism, targeting both ITK and JAK3, offers a potential first-in-class oral therapy that could address the disease at multiple points in its immune pathology. If successful, this could provide a much-needed effective treatment option, improving the quality of life for thousands of patients who currently endure chronic pain, itching, and discomfort, and face risks such as malignancy in oral LP.
What's Next?
Aclaris Therapeutics anticipates releasing top-line results from the oral erosive lichen planus (OLP) cohort of the ALPHA trial in the second half of 2027. The trial is structured to include three patient cohorts: OLP, cutaneous lichen planus (CLP), and lichen planopilaris (LPP), with primary endpoints varying by cohort. Beyond modzatinib, Aclaris also plans to file an Investigational New Drug (IND) application for ATI-9494 (an ITK/TXK inhibitor) this quarter, with a Phase 1 clinical program expected to begin in the first quarter of 2027. These upcoming milestones indicate a continued focus on developing novel treatments for immuno-inflammatory diseases, potentially expanding the company's pipeline and addressing other conditions with limited therapeutic options.
Beyond the Headlines
The development of modzatinib highlights a broader trend in biopharmaceutical research towards precision medicine, focusing on specific immune pathways implicated in inflammatory diseases. The dual inhibition of ITK and JAK3 represents a sophisticated approach to modulating immune responses, potentially offering more targeted and effective treatments with fewer side effects compared to broader immunosuppressants. The FDA's Fast Track Designation underscores the urgency and significant unmet need in treating lichen planus, reflecting a regulatory environment that prioritizes therapies for serious conditions with no existing treatments. This could pave the way for faster development and review processes, accelerating access to innovative medicines for patients suffering from similar complex immune-mediated disorders.













